ALFA Filings
Every announcement, straight from the exchange
Every Windlas Biotech merger & restructuring announcement on NSE and BSE, newest first, each with its own page.
Time
10 announcements
Windlas Biotech extinguished 4,70,000 shares following a ₹47 Crore buyback at ₹1,000 per share. The move reduces equity capital and enhances shareholder value.
Windlas Biotech Limited completed a ₹47 Crore share buyback via tender offer. The company repurchased 4,70,000 equity shares, reducing its total paid-up share capital.
Windlas Biotech Limited announced a share buyback of 4,70,000 equity shares at ₹1,000 per share via a tender offer, totaling ₹47.00 Crore. The buyback window opens on April 30, 2026, and closes on May 7, 2026. This corporate action aims to return capital to shareholders at a significant premium.
Windlas Biotech Limited announced a ₹47 Crore share buyback via tender offer at ₹1,000 per share. The offer opens on April 30, 2026, and closes on May 7, 2026. The company intends to repurchase 4,70,000 shares, representing a significant return of capital to shareholders.
Windlas Biotech Limited announced a buyback of 4,70,000 equity shares at ₹1,000 per share, totaling ₹47 Crore via a tender offer. The buyback opens on April 30, 2026, and closes on May 7, 2026. Promoters will not participate in the offer, which aims to return capital to shareholders.
Windlas Biotech Ltd has issued a Letter of Offer for the buyback of up to 4,70,000 equity shares at ₹1,000 per share. The ₹47 Crore buyback will be conducted via the tender offer route from April 30 to May 07, 2026, for eligible shareholders as on the April 24 record date.
Windlas Biotech Limited announced a buyback of 4,70,000 equity shares at ₹1,000 per share, totaling ₹47 Crore. The buyback will be conducted via a tender offer on a proportionate basis for shareholders as of the April 26, 2026 record date.
Windlas Biotech Limited's board approved a ₹47 Crore equity share buyback via tender offer at ₹1000 per share. The company proposes to buy back 4,70,000 shares, representing 2% of its existing paid-up capital. The record date for the offer is fixed as April 24, 2026.
Windlas Biotech Limited approved a buyback of up to 4,70,000 equity shares at ₹1,000 per share, totaling ₹47 Crore. The buyback represents 2.23% of total equity and will be conducted via a tender offer. The record date for eligibility is fixed for April 24, 2026.
Windlas Biotech Limited has scheduled a Board meeting on April 17, 2026, to consider a proposal for the buyback of its fully paid-up equity shares. Trading window for designated persons remains closed from April 1, 2026, until 48 hours after the declaration of financial results for the year ended March 31, 2026.